Loading clinical trials...
Loading clinical trials...
A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.
Age
All ages
Sex
FEMALE
Healthy Volunteers
No
Birmingham, Alabama, United States
Columbiana, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Montgomery, Alabama, United States
Chandler, Arizona, United States
Gilbert, Arizona, United States
Paradise Valley, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Start Date
June 1, 2004
Primary Completion Date
April 1, 2006
Completion Date
April 1, 2006
Last Updated
November 2, 2016
1,711
ACTUAL participants
Ibandronate
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT05010590
NCT07329543
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05060380